Company: BIVIW
Filing Date: 2025-07-22
Form Type: S-1/A
Source: 0001520138-25-000216
Chunk: 115

Company: BIOVIE INC.
Filing Date: 2025-07-22
Form: S-1/A
Chunk 115
---
 of
Directors since 2023 and has served as the Company’s director since 2016. He is currently CEO of EVERSANA, the leading commercialization
services company for the life sciences industry. In five years since he founded EVERSANA, it is now over $1B in revenue, with >7000
employees across 40 global locations. He formerly served as the CEO of Decision Resources Group (DRG), which he transformed into a leading
healthcare data and analytics firm. Prior to that, Jim was CEO of IHS Cambridge Energy Research Associates (IHS CERA), a recognized leader
in energy industry subscription information products, and formerly the President of Strategic Decisions Group (SDG), a leading global
strategy consultancy. Mr. Lang holds a BS summa cum laude in electrical and computer engineering from the University of New Hampshire
and an MBA with Distinction from the Tuck School of Business. Jim Lang currently also serves as a Director at OptimizeRX (OPRX), a Nasdaq
listed Company.

Jim Lang’s qualifications to serve on our Board of Directors
are primarily based on his decades of experience as a strategy consultant, broad industry expertise, and senior-level management experience
running several healthcare and information technology companies.

Dr. Amy S. Chappell has served as a director
of the Company since 2025. Since 2024, she has served as CMO of Solaxa Inc., where she oversees clinical development of novel therapies
for ataxia and nerve repair. Prior to that, Dr. Chappell was a clinical trials and neurology consultant for various companies from 2021
to 2024. From 2020 to 2021, she was CMO of Eliem Therapeuetics, assisting it through a successful initial public offering and advancing
programs in epilepsy and mood disorders. Dr. Chappell has also served over 25 years at Eli Lilly & Co., where she played a central
role in developing and gaining US Food and Drug Administration (FDA) approvals for multiple central nervous system indications, including
for Cymbalta® in fibromyalgia and musculoskeletal pain. Dr. Chappell holds a BA from Antioch College and an MD from Indiana University
School of Medicine. She also holds numerous patents, has authored over 100 peer-reviewed publications and presentations, and remains a
Fellow of the American Academy of Neurology.

Dr. Chappell’s qualifications to serve on
our